Clinical Trials Browser

Phase 1/2 × LY3295668 erbumine × Clear all

NCT05017025 2026-05-20

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Lung Neoplasms

NCT03092934 2021-07-02

A Study of AK-01 (LY3295668) in Solid Tumors

Phase 1/2 Completed

13 enrolled 17 charts

BreastHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms